Novel targets for immune-checkpoint inhibition in cancer

Over the last decade, immune-checkpoint inhibitors (ICI) have revolutionized cancer care, offering patients an alternative to chemotherapy or targeted therapies and a chance at long-term remission across many tumor types. The first two immune-checkpoint receptors for which clinically efficient inhibitors were successfully developed were the cytotoxic lymphocyte antigen-4 (CTLA-4) and the programmed death-1 (PD-1) receptor. Most solid tumors and a subset of hematologic malignancies benefit from using one or both drug classes.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research